A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous Cell Carcinoma
D. Schadendorf,
S. Koyfman,
A.W. Silk,
D. Davar,
J. Clark,
R. Ladwa,
J. Lee,
L.H. Suttner,
R. Groisberg,
F. Jin,
G. Hanna
Affiliations
D. Schadendorf
Universitaetsklinikum Essen, Essen, Germany
S. Koyfman
Cleveland Clinic, Cleveland, OH, United States of America
A.W. Silk
Dana-Farber Cancer Institute, Boston, MA, United States of America
D. Davar
University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America
J. Clark
Chris O’Brien Lifehouse, Camperdown, NSW, Australia
R. Ladwa
Princess Alexandra Hospital, Brisbane, QLD, Australia
J. Lee
Chris O’Brien Lifehouse, Camperdown, NSW, Australia
L.H. Suttner
Merck & Co., Inc., Rahway, NJ, United States of America
R. Groisberg
Merck & Co., Inc., Rahway, NJ, United States of America
F. Jin
Merck & Co., Inc., Rahway, NJ, United States of America
G. Hanna
Dana-Farber Cancer Institute, Boston, MA, United States of America
